3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Renal Cell
21
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Kidney Neoplasms
5
von Hippel-Lindau Disease
4
Pheochromocytoma
2
Paraganglioma
2
Neoplasm Metastasis
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Ovarian Neoplasms
1
Neuroectodermal Tumors, Primitive
1
Metastatic Castration-Resistant Prostate Cancer
1
Hemangioblastoma
1
Glioblastoma
1
Endometrial Neoplasms
1
Clear-cell metastatic renal cell carcinoma
1
Carcinoma
1
Breast Neoplasms
1
Adenoma, Islet Cell
1
Interventions
Cyclophosphamide
6
Vincristine
3
Temozolomide
3
Radiotherapy
3
Cisplatin
3
Automobiles
3
fludarabine
2
Etoposide
2
Eflornithine
2
Carboplatin
2
omburtamab I-131
1
ibrutinib
1
gallium Ga 68 dotatate
1
etoposide phosphate
1
belzutifan
1
Zoledronic Acid
1
Thiotepa
1
Tamoxifen
1
Standard of Care
1
Radiotherapy, Image-Guided
1
Pemetrexed
1
ONC206
1
Nivolumab
1
Mesna
1
Maintenance Chemotherapy
1
Lomustine
1
Isotretinoin
1
Induction Chemotherapy
1
Hydrocortisone
1
HhAntag691
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive
×
belzutifan
×
1 year
×
Clear all
NCT07167329
2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2
Recruiting
100 enrolled